Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy M Shefner

Showing results (61-70 of 105) with videos related to

Pageof 11
Sort By:
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|September 28, 2007
Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trialsSeward B Rutkove, Hui Zhang, David A Schoenfeld, et al.
Environmental Health Perspectives|August 5, 2003
Amyotrophic lateral sclerosis, lead, and genetic susceptibility: polymorphisms in the delta-aminolevulinic acid dehydratase and vitamin D receptor genesFreya Kamel, David M Umbach, Teresa A Lehman, et al.
Brain : a Journal of Neurology|June 16, 2023
Skeletal muscle in amyotrophic lateral sclerosisJeremy M Shefner, Antonio Musaro, Shyuan T Ngo, et al.
Muscle & Nerve|June 14, 2008
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosisMerit E Cudkowicz, Jeremy M Shefner, Elizabeth Simpson, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 1, 2021
Noninvasive ventilation use by patients enrolled in VITALITY-ALSStacy A Rudnicki, Jinsy A Andrews, Amy Bian, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 14, 2019
A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosisJeremy M Shefner, Merit E Cudkowicz, Orla Hardiman, et al.
Muscle & Nerve|January 19, 2026
The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALSStacy A Rudnicki, Elisa Giacomelli, Katherine Herder, et al.
JAMA Neurology|October 17, 2022
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A ReviewJeremy M Shefner, Richard Bedlack, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 12, 2022
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trialPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Pageof 11

Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|September 28, 2007
Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trialsSeward B Rutkove, Hui Zhang, David A Schoenfeld, et al.
Environmental Health Perspectives|August 5, 2003
Amyotrophic lateral sclerosis, lead, and genetic susceptibility: polymorphisms in the delta-aminolevulinic acid dehydratase and vitamin D receptor genesFreya Kamel, David M Umbach, Teresa A Lehman, et al.
Brain : a Journal of Neurology|June 16, 2023
Skeletal muscle in amyotrophic lateral sclerosisJeremy M Shefner, Antonio Musaro, Shyuan T Ngo, et al.
Muscle & Nerve|June 14, 2008
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosisMerit E Cudkowicz, Jeremy M Shefner, Elizabeth Simpson, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 1, 2021
Noninvasive ventilation use by patients enrolled in VITALITY-ALSStacy A Rudnicki, Jinsy A Andrews, Amy Bian, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 14, 2019
A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosisJeremy M Shefner, Merit E Cudkowicz, Orla Hardiman, et al.
Muscle & Nerve|January 19, 2026
The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALSStacy A Rudnicki, Elisa Giacomelli, Katherine Herder, et al.
JAMA Neurology|October 17, 2022
Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A ReviewJeremy M Shefner, Richard Bedlack, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 12, 2022
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trialPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Pageof 11